Resumen

SANCHEZ VEGA, Juan Diego  y  ZAMORANO GOMEZ, José Luis. Evolution in the management of dyslipidemia: comparative analysis of the 2019 ESC versus 2018 ACC/AHA guidelines. Rev.Urug.Cardiol. [online]. 2019, vol.34, n.3, pp.381-400.  Epub 01-Dic-2019. ISSN 0797-0048.  https://doi.org/10.29277/cardio.34.3.27.

Treatment of dyslipidemia has shown constant changes in the last decade. The emergence of several clinical trials with huge lipid lowering power, fundamentally cholesterol absorption inhibitors and PCSK9 inhibitors, has caused a change in the treatment perspective and an upgrade in patient control. At the same time, there has emerged various studies regarding the individual risk in certain situations, such as diabetes or familial hypercholesterolemia. They have helped to improve the stratification of patients and have contributed with ample data about best cholesterol levels to prevent cardiovascular disease. We have also now more tools for the individualization of patients' risk. Image tests have developed in such way that can change the perception of health and illness, even in early stages of the disease and asymptomatic patients. All these changes have resulted in appearance of new clinical practice guidelines, being the analysis of the most current (ACC/AHA (American College of Cardiology/American Heart Association) 2018 and ESC (European Society of Cardiology) 2019) the purpose of this article.

Palabras clave : Dyslipidemias; Practice guidelines; Pharmacotherapy.

        · resumen en Español | Portugués     · texto en Español     · Español ( pdf )